Ankündigung • Jun 30
B-SOFT Co.,Ltd. to Report First Half, 2026 Results on Aug 29, 2026 B-SOFT Co.,Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Yun Ling was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 29
B-SOFT Co.,Ltd., Annual General Meeting, May 21, 2026 B-SOFT Co.,Ltd., Annual General Meeting, May 21, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Hangzhou, Zhejiang China Ankündigung • Mar 31
B-SOFT Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026 B-SOFT Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Ankündigung • Dec 31
B-SOFT Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 15, 2026 B-SOFT Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 15, 2026 Ankündigung • Sep 30
B-SOFT Co.,Ltd. to Report Q3, 2025 Results on Oct 23, 2025 B-SOFT Co.,Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025 Ankündigung • Jul 02
B-SOFT Co.,Ltd. to Report First Half, 2025 Results on Aug 27, 2025 B-SOFT Co.,Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Ankündigung • Apr 15
B-SOFT Co.,Ltd., Annual General Meeting, May 29, 2025 B-SOFT Co.,Ltd., Annual General Meeting, May 29, 2025, at 14:30 China Standard Time. Location: 3F, No. 708, Jianta Street, Puyan Subdistrict, Binjiang District, Hangzhou, Zhejiang China Ankündigung • Mar 31
B-SOFT Co.,Ltd. to Report Q1, 2025 Results on Apr 28, 2025 B-SOFT Co.,Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025 Ankündigung • Dec 31
B-SOFT Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025 B-SOFT Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.031 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.01 (down from CN¥0.031 in 3Q 2023). Revenue: CN¥441.9m (down 2.4% from 3Q 2023). Net income: CN¥25.4m (down 62% from 3Q 2023). Profit margin: 5.7% (down from 15% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Ankündigung • Sep 30
B-SOFT Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024 B-SOFT Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.01 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.01 (in line with 2Q 2023). Revenue: CN¥351.2m (down 1.3% from 2Q 2023). Net income: CN¥15.0m (up 10% from 2Q 2023). Profit margin: 4.3% (up from 3.8% in 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Ankündigung • Jun 29
B-SOFT Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024 B-SOFT Co.,Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • May 25
Dividend of CN¥0.01 announced Dividend of CN¥0.01 is the same as last year. Ex-date: 31st May 2024 Payment date: 31st May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.9%. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.01 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.01 (in line with 1Q 2023). Revenue: CN¥375.5m (up 7.8% from 1Q 2023). Net income: CN¥12.4m (up 19% from 1Q 2023). Profit margin: 3.3% (up from 3.0% in 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 14
Full year 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.03 in FY 2022) Full year 2023 results: EPS: CN¥0.02 (down from CN¥0.03 in FY 2022). Revenue: CN¥1.62b (up 5.8% from FY 2022). Net income: CN¥36.7m (down 14% from FY 2022). Profit margin: 2.3% (down from 2.8% in FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 13
B-SOFT Co.,Ltd., Annual General Meeting, May 16, 2024 B-SOFT Co.,Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Ankündigung • Mar 30
B-SOFT Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 B-SOFT Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Ankündigung • Dec 29
B-SOFT Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 B-SOFT Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 26, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.039 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.031 (down from CN¥0.039 in 3Q 2022). Revenue: CN¥452.5m (up 26% from 3Q 2022). Net income: CN¥67.4m (down 2.9% from 3Q 2022). Profit margin: 15% (down from 19% in 3Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Ankündigung • Oct 17
B-SOFT Co.,Ltd Appoints Chen Zhongyang as Non-Independent Directors B-SOFT Co.,Ltd. at its extraordinary general meeting of 2023 held on 13 October 2023, approved the election and nomination of Chen Zhongyang as non-independent directors, cumulative voting system applicable. Ankündigung • Sep 30
B-SOFT Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023 B-SOFT Co.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023 Board Change • Sep 02
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Yun Ling was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.007 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.01 (up from CN¥0.007 in 2Q 2022). Revenue: CN¥356.0m (up 12% from 2Q 2022). Net income: CN¥13.6m (up 47% from 2Q 2022). Profit margin: 3.8% (up from 2.9% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 29
B-SOFT Co.,Ltd. Announces Management Changes B-SOFT Co.,Ltd. at its 1st Extraordinary General Meeting of 2023 on 25 August 2023, during which the following proposal(s) was/were approved: Election and nomination of non-independent directors, cumulative voting system applicable: Zhang Lvzheng, Hu Yan, Ying Jing, Ge Boxiu, KWOK WAI ANDY HO, and Ye Jiang. Election and nomination of independent directors, cumulative voting system applicable: Ling Yun. Election and nomination of non-employee supervisors, cumulative voting system applicable: Ye Jian and Jia Chi. Ankündigung • Aug 23
B-SOFT Co.,Ltd. (SZSE:300451) announces an Equity Buyback for CNY 60 million worth of its shares. B-SOFT Co.,Ltd. (SZSE:300451) announces a share repurchase program. Under the program, the company will repurchase up to CNY 60 million worth of its shares. The shares will be repurchased at a price not more than CNY 10 per share. The repurchased shares will be used for ESOP or equity incentives. The program will be valid for a period of 12 months. Ankündigung • May 23
B-SOFT Co.,Ltd. Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 26 May 2023 B-SOFT Co.,Ltd. announced 2022 final profit distribution plan to be implemented (A shares) as Cash dividend/10 shares (tax included): CNY 0.10000000. Record date: 25 May 2023, Ex-date: 26 May 2023, Payment date: 26 May 2023. Reported Earnings • Apr 15
Full year 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.27 in FY 2021) Full year 2022 results: EPS: CN¥0.03 (down from CN¥0.27 in FY 2021). Revenue: CN¥1.53b (down 20% from FY 2021). Net income: CN¥42.6m (down 90% from FY 2021). Profit margin: 2.8% (down from 22% in FY 2021). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 7% per year. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Jianqiu Liang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.061 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.039 (down from CN¥0.061 in 3Q 2021). Revenue: CN¥358.2m (down 17% from 3Q 2021). Net income: CN¥69.4m (down 21% from 3Q 2021). Profit margin: 19% (in line with 3Q 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥7.07, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 31x in the Healthcare Services industry in Asia. Total loss to shareholders of 23% over the past three years. Board Change • Sep 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Jianqiu Liang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.007 (vs CN¥0.031 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.007 (down from CN¥0.031 in 2Q 2021). Revenue: CN¥317.4m (down 16% from 2Q 2021). Net income: CN¥9.27m (down 82% from 2Q 2021). Profit margin: 2.9% (down from 14% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 38%, compared to a 20% growth forecast for the Healthcare Services industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • May 31
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Jia Mei Cai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.062 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.06. Revenue: CN¥463.0m (up 15% from 1Q 2021). Net income: CN¥92.2m (up 2.1% from 1Q 2021). Profit margin: 20% (down from 23% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 18% growth forecast for the industry in China. Reported Earnings • Apr 16
Full year 2021 earnings released: EPS: CN¥0.27 (vs CN¥0.22 in FY 2020) Full year 2021 results: EPS: CN¥0.27 (up from CN¥0.22 in FY 2020). Revenue: CN¥1.90b (up 16% from FY 2020). Net income: CN¥413.0m (up 24% from FY 2020). Profit margin: 22% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 20%, compared to a 19% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥11.18, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 68% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.94 per share. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.061 (vs CN¥0.054 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥431.5m (up 5.6% from 3Q 2020). Net income: CN¥87.5m (up 17% from 3Q 2020). Profit margin: 20% (up from 18% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.031 (vs CN¥0.022 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥375.8m (down 1.5% from 2Q 2020). Net income: CN¥52.1m (up 51% from 2Q 2020). Profit margin: 14% (up from 9.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.05 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥402.2m (up 23% from 1Q 2020). Net income: CN¥90.4m (up 56% from 1Q 2020). Profit margin: 23% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥13.03, the stock is trading at a trailing P/E ratio of 48.6x, up from the previous P/E ratio of 41.4x. This compares to an average P/E of 98x in the Healthcare Services industry in China. Total returns to shareholders over the past three years are 86%. Is New 90 Day High Low • Jan 26
New 90-day low: CN¥12.20 The company is down 10.0% from its price of CN¥13.50 on 29 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.21 per share. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥12.27 The company is down 21% from its price of CN¥15.45 on 14 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥18.92 per share. Is New 90 Day High Low • Dec 25
New 90-day low: CN¥12.61 The company is down 16% from its price of CN¥15.06 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥18.48 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥296.5m, up 3.6% from the prior year. Total revenue was CN¥1.66b over the last 12 months, up 16% from the prior year. Is New 90 Day High Low • Oct 19
New 90-day low: CN¥14.72 The company is down 21% from its price of CN¥18.61 on 21 July 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.50 per share. 
